Modulation of renin-angiotensin system may slow conversion from mild cognitive impairment to Alzheimer's disease

Journal of the American Geriatrics Society

Volumn 63, Issue 9, 2015, Pages 1749-1756

  Wharton, Whitney ^a   Goldstein, Felicia C ^a   Zhao, Liping ^a   Steenland, Kyle ^b   Levey, Allan I ^a   Hajjar, Ihab ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; blood pressure; cognition; hypertension; mild cognitive impairment; renin angiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

AFRICAN AMERICAN; AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; BLOOD BRAIN BARRIER; BOSTON NAMING TEST; CAUCASIAN; CLINICAL DEMENTIA RATING; CONTROLLED STUDY; DEMENTIA ASSESSMENT; DIGIT SPAN FORWARD; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LANGUAGE; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; RACE DIFFERENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; COMPLICATION; DISEASE COURSE; PATHOPHYSIOLOGY; TIME;

AGED; ALZHEIMER DISEASE; ANTIHYPERTENSIVE AGENTS; BLOOD-BRAIN BARRIER; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; MALE; MILD COGNITIVE IMPAIRMENT; RENIN-ANGIOTENSIN SYSTEM; TIME FACTORS;

EID: 84942155694     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.13627     Document Type: Article

References (31)

1. Kivipelto M, Helkala EL, Hanninen T, et al., Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology 2001; 56: 1683-1689.
2. Ohrui T, Tomita N, Sato-Nakagawa T, et al., Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004; 63: 1324-1325.
3. Guimarães FC, Amorim PR, Reis FF, et al., Physical activity and better medication compliance improve Mini-Mental State Examination scores in the elderly. Dement Geriatr Cogn Disord 2015; 39: 25-31.
4. Sperling RA, Aisen PS, Beckett LA, et al., Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-292.
5. Craft S,. The role of metabolic disorders in Alzheimer disease and vascular dementia: Two roads converged. Arch Neurol 2009; 66: 300-305.
6. Savaskan E, Hock C, Olivieri G, et al., Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging 2001; 22: 541-546.
7. Miners JS, Ashby E, Van Helmond Z, et al., Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 2008; 34: 181-193.
8. Miners JS, van Helmond Z, Raiker M, et al., ACE variants and association with brain Abeta levels in Alzheimer's disease. Am J Transl Res 2010; 3: 73-80.
9. Sink KM, Leng X, Williamson J, et al., Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: Results from the Cardiovascular Health Study. Arch Intern Med 2009; 169: 1195-1202.
10. Wharton W, Stein JH, Korcarz C, et al., The effects of ramipril in individuals at risk for Alzheimer's disease: Results of a pilot clinical trial. J Alzheimers Dis 2012; 32: 147-156.
11. Barnes JM, Barnes NM, Costall B, et al., Angiotensin II inhibits the release of [3H]acetylcholine from rat entorhinal cortex in vitro. Brain Res 1989; 491: 136-143.
12. Ohrui T, Matsui T, Yamaya M, et al., Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc 2004; 52: 649-650.
13. Weintraub S, Salmon D, Mercaldo N, et al., The Alzheimer's Disease Centers' Uniform Data Set (UDS): The neuropsychologic test battery. Alzheimer Dis Assoc Disord 2009; 23: 91-101.
14. Albert MS, DeKosky ST, Dickson D, et al., The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-279.
15. Wechsler D,. Wechsler Memory Scale-Revised Manual. San Antonio, TX: The Psychological Corporation, 1987.
16. Dodrill C,. A neuropsychological battery for epilepsy. Epilepsia 1978; 19: 611-623.
17. Kaplan E, Goodglass H, Weintraub S,. The Boston Naming Test, 2nd Ed. Philadelphia: Lea & Febiger, 1983.
18. Spreen O, Strauss E,. A Compendium of Neuropsychological Tests, 2nd Ed. New York: Oxford University Press, 1998.
19. Wechsler D,. Wechsler Adult Intelligence Scale. New York: Psychological Corporation, 1955.
20. Folstein MF, Folstein SE, McHugh PR,. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
21. Hughes CP, Berg L, Danziger WL, et al., A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566-572.
22. Devanand DP, Folz M, Gorlyn M, et al., Questionable dementia: Clinical course and predictors of outcome. J Am Geriatr Soc 1997; 45: 321-328.
23. Deschaintre Y, Richard F, Leys D, et al., Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 2009; 73: 674-680.
24. Yasar S, Xia J, Yao W, et al., Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology 2013; 81: 896-903.
25. Hajjar I, Hart M, Chen YL, et al., Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: Results of a pilot randomized clinical trial. J Am Geriatr Soc 2013; 61: 194-201.
26. Wang J, Ho L, Chen L, et al., Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007; 117: 3393-3402.
27. Hajjar I, Brown L, Mack WJ, et al., Impact of angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Arch Neurol 2012; 69: 1632-1638.
28. Onder G, Penninx BW, Balkrishnan R, et al., Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: An observational study. Lancet 2002; 359: 926-930.
29. O'Caoimh R, Healy L, Gao Y, et al., Effects of centrally acting Angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer's disease. J Alzheimers Dis 2014; 40: 595-603.
30. Pelisch N, Hosomi N, Mori H, et al., RAS inhibition attenuates cognitive impairment by reducing blood- brain barrier permeability in hypertensive subjects. Curr Hypertens Rev 2013; 9: 93-98.
31. Manly JJ, Jacobs DM, Sano M, et al., Effect of literacy on neuropsychological test performance in nondemented, education-matched elders. J Int Neuropsychol Soc 1999; 5: 191-202.